DEF: Venus Concept Seeks Stockholder Approval for Share Issuance Related to Preferred Stock Conversions

Venus Concept is asking stockholders to approve the issuance of common stock upon the conversion of several series of preferred stock and a convertible note at the upcoming Annual and Special Meeting of Stockholders on June 25, 2025.

Summary

• Venus Concept Inc. is holding its Annual and Special Meeting of Stockholders on June 25, 2025.
• The meeting will be held online.
• Stockholders will vote on several proposals, including the election of three directors and the ratification of MNP LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• A key focus is to approve the issuance of common stock upon the conversion of Series Y Preferred Stock (up to 10,544,354 shares), Series X Preferred Stock (up to 271,819 shares), Senior Preferred Stock (up to 381,981 shares), and the October 2023 Convertible Note (up to 64,454 shares).
• These approvals are required under Nasdaq Listing Rules, primarily Rule 5635(b) and 5635(d), to eliminate limits on conversions that could result in a change of control or were issued below the minimum price.
• The Board recommends voting FOR all proposals.
• The record date for determining stockholders eligible to vote is April 28, 2025.
• The company is seeking approval to issue up to 10,544,354 shares of common stock upon conversion of Series Y Preferred Stock.
• The company is seeking approval to issue up to 271,819 shares of common stock upon conversion of Series X Preferred Stock.
• The company is seeking approval to issue up to 381,981 shares of common stock upon conversion of Senior Preferred Stock.
• The company is seeking approval to issue up to 64,454 shares of common stock upon conversion of the October 2023 Convertible Note.

Sentiment

Score: 6

Explanation: The document is primarily factual and procedural, related to corporate governance and required approvals. While there are potential benefits to the company's financial structure, the risk of dilution tempers the overall sentiment.

Positives

• Approving the proposals would simplify the company's capitalization structure.
• Conversion of preferred stock would reduce the aggregate liquidation preference overhanging the common stock.
• The debt restructuring initiatives, including the exchange transactions, have reduced the company's outstanding debt and cured a listing deficiency on the Nasdaq Capital Market.
• The sales of Senior Preferred Stock improved the company's liquidity position in the 2023 fiscal year, providing funding for continuing operations and potential future growth.

Negatives

• The potential issuance of common stock upon conversion of preferred stock and convertible notes would result in dilution of existing stockholders' percentage ownership.
• Such issuances could create downward pressure on, or increase volatility of, the trading price of the company's common stock.

Risks

• Failure to obtain stockholder approval for the proposals would mean conversions of preferred stock and convertible notes would remain limited under Nasdaq Listing Rules.
• The company may need to incur additional costs and expend additional resources to seek approval at later meetings if the proposals are not approved at the Annual Meeting.
• The company faces challenging capital market conditions, economic environment impacts on customers, supply challenges, and headwinds within the overall medical aesthetic industry.

Future Outlook

The company believes that simplifying its capitalization structure through the conversion of preferred stock may help it raise additional capital or pursue other strategic opportunities in the future.

Industry Context

The document does not explicitly detail the broader industry trends, but the company's actions to restructure debt and improve its balance sheet suggest it is operating in a challenging environment, possibly due to macroeconomic factors or industry-specific headwinds in the medical aesthetics sector.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards or benchmarks.
• Without additional information, it is difficult to assess the company's performance relative to its peers.
• Comparable companies in the medical aesthetics industry include Cutera, Inc. and ZELTIQ Aesthetics, Inc. (acquired by Allergan, Inc.).
• These companies, like Venus Concept, operate in a competitive market and face similar challenges related to innovation, market adoption, and regulatory compliance.

Related Party Transactions

• The company entered into exchange agreements with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP, holders of more than 10% of the company's outstanding securities.
• The company entered into a Note Purchase and Registration Rights Agreement with EW Healthcare Partners, L.P. and EW Healthcare Partners-A, L.P., with Mr. Barry, a member of the Board, affiliated with the Investors who hold more than 5% of our outstanding common stock.
• The company entered into an agreement with certain investors to issue and sell up to $9,000,000 in shares of preferred stock which are convertible into common stock on a 1:0.2424 basis (the 2023 Multi-Tranche Private Placement), from time to time until December 31, 2025.
• The company and EW Entities entered into a Resale Registration Rights Agreement (the 2023 Registration Rights Agreement).

Stakeholder Impact

• Existing stockholders face potential dilution of their ownership if the proposals are approved and the preferred stock and convertible notes are converted into common stock.
• The conversion of preferred stock could improve the return to common stock in a liquidation scenario.
• The company's actions to restructure debt and improve its balance sheet could benefit all stakeholders by strengthening the company's financial position.

Next Steps

• Stockholders will vote on the proposals at the Annual and Special Meeting on June 25, 2025.
• The company will file a Current Report on Form 8-K within four business days after the Annual Meeting to announce the voting results.

Key Dates

Keywords

proxy statement, stockholder meeting, preferred stock, common stock, share issuance, conversion, Nasdaq, MNP LLP, directors, voting rights, dilution, debt restructuring